NIAID Site Search

This template outlines the required elements and layout of a Letter of Amendment.

Last Reviewed: August 6, 2019

This testimony given by Hugh Auchincloss outlines the importance of NIH biodefense research infrastructure for protecting public heatlh.

Last Reviewed: August 6, 2019

Outline of changes to pharmacy guidelines from NIAID Division of Allergy, Immunology, and Transplantation

Last Reviewed: July 9, 2019

Lead Institution: University of California, San Francisco Research Areas Uganda is emblematic of the challenges faced by high burden countries, where routine surveillance systems are inadequate to assess trends in the burden of malaria or to monitor the impact of control interventions. Through PRISM, researchers have implemented a comprehensive malaria surveillance program including enhanced

Last Reviewed: July 12, 2024

NIH Opening Statement Senate LHHS FY 2019 Hearing: Prepared statement of Lawrence A. Tabak, D.D.S., PH.D., Principal Deputy Director, Office of the Director

Last Reviewed: August 16, 2018

This poster provides information about the progress that has been made in developing a safe, effective, and preventive HIV vaccine.

Last Reviewed: May 17, 2018

A NIAID-sponsored Phase 2 clinical trial will evaluate potential new therapeutics for COVID-19.

Published: August 4, 2020

Computational and quantitative experimental cell biology and immunology

Last Reviewed: May 17, 2024

Our talented research group supports the vision and clinical and translational studies of the lab.

Last Reviewed: May 6, 2025

Learn who reviews your application at NIH, the role of different reviewers, how to interpret your summary statement, and next steps.

Last Reviewed: April 25, 2025

DAIDS Specific Informed Consent Template General Use. Version 2.0; Posted 5 December 2017

Last Reviewed: December 1, 2017

NIAID Expert Panel provided addendum guidelines for the prevention of peanut allergy in the United States.

Last Reviewed: January 19, 2017

A NIAID-supported Phase 3 clinical trial evaluating an investigational COVID-19 vaccine called AZD1222 will enroll around 30,000 adult volunteers.

Published: August 31, 2020

Lead Institution: University of California, Irvine, USA ICEMR website: https://www.icemreastafrica.org/ Research Areas The overall goal of this project is to assess the impact of Anopheles stephensi invasion and spread on malaria epidemiology and transmission, develop efficient tools and methods for surveillance of An. stephensi, and identify cost-effective vector control methods that can be

Last Reviewed: July 12, 2024

NIAID’s strategic plan for the discovery and development of adjuvants, vaccine components that augment and target immune responses.

Last Reviewed: November 8, 2016

Sample application from Timothy C. Fong, Ph.D., for Small Business Innovation Research (SBIR) grant (R41).

Last Reviewed: October 27, 2016

LMIV Vaccine Development Unit develops and performs clinical evaluation of prototype malaria vaccines. The VDU focuses on research to eradicate malaria through development of a vaccine to interrupt malaria transmission, including transmission-blocking components and pre-erythrocytic components. The VDU also designs and develops vaccines specifically to protect pregnant women and their infants.

Last Reviewed: November 21, 2022

NIAID Pharmacy Establishment Plan form for Division of Allergy, Immunology, and Transplantation (DAIT)-funded/sponsored clinical research sites.

Last Reviewed: October 4, 2016

Data management requirements for Division of Microbiology and Infectious Diseases (DMID)-sponsored clinical research

Last Reviewed: July 26, 2016

The research career development award category is broad and special rules may apply for your award. Before jumping in to write your application, be sure to do the following: Find our instructions and application advice for each award type linked on the main Research Career Development (K) Awards page. Carefully read the relevant notice of funding opportunity (NOFO). Follow the supplemental

Last Reviewed: October 4, 2024

A NIAID-supported Phase 3 clinical trial designed to evaluate if an investigational vaccine can prevent symptomatic COVID-19 in adults has begun.

Published: July 27, 2020

Together with our partners, the National Institutes of Health (NIH) commemorates World AIDS Day and affirms our commitment to bolstering the extraordinary gains achieved in HIV science and to persevering until we end HIV-related illness and stigma. As we mark this observance, we celebrate the people who enable scientific progress, honor the loved ones and leaders we have lost, and reflect on the work that remains to ensure the health and life quality of all people affected by, and living with, HIV.

Published: December 2, 2024

NIH has established a policy for the use of NIH funds for research involving select agents.

Last Reviewed: October 17, 2023

NIH published RFA-AI-24-023, U.S.-South Africa Program for Collaborative Biomedical Research – Phase 3 (HIV/AIDS) (R01, Clinical Trial Optional) notice of funding opportunity (NOFO) on September 17, 2024. Updated November 6, 2024. We added the questions and answers under Application, Eligibility, Funding and Budget, and Research. Table of Contents General Application Eligibility Funding and Budget

Last Reviewed: November 7, 2024

Information for researchers about which changes can be made to grants independently and which require NIAID permission.

Last Reviewed: September 29, 2023